Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: Characteristics of metabolic syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 9, 2012, Pages 2289-2294

  Olson, Eric J ^a   Pearce, Gregory L ^a   Jones, Nigel P ^a   Sprecher, Dennis L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

free fatty acid insulin; metabolic syndrome; peroxisome proliferator activated receptor ; serum lipids

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; APOLIPOPROTEIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; EXPLORATORY RESEARCH; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPOCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PPAR GAMMA; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84865507796     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.247890     Document Type: Article

References (23)

1. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA. 2001;98:5306-5311.
2. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA. 2003;100:15924-15929.
3. Willson TM, Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol. 1997;1:235-241.
4. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
5. Fürnsinn C, Willson TM, Brunmair B. Peroxisome proliferator- activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia. 2007;50:8-17.
6. Risérus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57:332-339.
7. Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG. Triglyceride:high- density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol. 2007;27:359-365.
8. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 2001;56:239-263.
9. Qin X, Xie X, Fan Y, Tian J, Guan Y, Wang X, Zhu Y, Wang N. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology. 2008;48:432-441.
10. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-180.
11. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225-1236.
12. Otvos JD. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular risk: Clinical implications of lipoprotein quantification using NMR spectroscopy. J Lab Med. 2002;26:544-550.
13. Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003;88:4525-4532.
14. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis. 2002;164:1-13.
15. Thulin P, Glinghammar B, Skogsberg J, Lundell K, Ehrenborg E. PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells. Int J Mol Med. 2008;21:819-824.
16. Tall AR, Breslow JL, Rubin EM. Genetic disorders affecting plasma high-density lipoproteins. In: Scriver CR ed. The Metabolic and Molecular Basis of Inherited Disease, 8th ed. New York, NY: McGraw-Hill; 2001: 2915-2936.
17. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-1113.
18. Williams PT, Feldman DE. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis. 2011;214:196-202.
19. Barter PJ, Rye KA. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med. 2006;259:447-454.
20. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116:2029-2035.
21. Takahashi S, Tanaka T, Sakai J. New therapeutic target for metabolic syndrome: PPARdelta. Endocr J. 2007;54:347-357.
22. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003;113:159-170.
23. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2004;2:e294.